Observational studyPloS one2014
Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease.
Observational study in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2021Pooled it
- Pooled it
- Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.Respiratory research · 2018Trial
- Microbial profiling of community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease: a comprehensive molecular diagnostics study.Pneumonia (Nathan Qld.) · 2025Article
- Decreased capsaicin cough reflex sensitivity predicts hospitalisation due to COPD.BMJ open respiratory research · 2023Article
- A prediction model for hospital mortality in patients with severe community-acquired pneumonia and chronic obstructive pulmonary disease.Respiratory research · 2022Observational
- TheFrontiers in microbiology · 2021Article
- Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease.Science translational medicine · 2019Article
- Lifestyle and comorbid conditions as risk factors for community-acquired pneumonia in outpatient adults (NEUMO-ES-RISK project).BMJ open respiratory research · 2019Observational
- Article
- Is It Time to Change the Definition of Acute Exacerbation of Chronic Obstructive Pulmornary Disease? What Do We Need to Add?Medical sciences (Basel, Switzerland) · 2018Review
- Current Status of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.Chinese medical journal · 2018Review
- The mortality risk factor of community acquired pneumonia patients with chronic obstructive pulmonary disease: a retrospective cohort study.BMC pulmonary medicine · 2018Article
- [Pneumonia in immunocompromised patients].Der Pneumologe · 2018Article
- Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records.International journal of chronic obstructive pulmonary disease · 2017Observational
- Risk Factors for Pneumonia and the Effect of the Pneumococcal Vaccine in Patients With Chronic Airflow Obstruction.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2016Article
- Risk factors associated with mortality from pneumonia among patients with pneumoconiosis.Annals of occupational and environmental medicine · 2016Article
- Association of COPD With Risk for Pulmonary Infections Requiring Hospitalization in HIV-Infected Veterans.Journal of acquired immune deficiency syndromes (1999) · 2015Article
- Article
- Socio-demographic and comorbid risk factors for poor prognosis in patients hospitalized with community-acquired bacterial pneumonia in southeastern US.Heart & lung : the journal of critical careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCommunity-acquired pneumonia (CAP) is a frequent complication of chronic obstructive pulmonary disease (COPD), but previous studies are often contradictory.
objectivesWe aimed to ascertain the characteristics and outcomes of CAP in patients with COPD as well as to determine the risk factors for mortality and Pseudomonas aeruginosa pneumonia in COPD patients with CAP. We also describe the etiology and outcomes of CAP in COPD patients receiving chronic oxygen therapy at home and those receiving inhaled steroids.
methodsAn observational analysis of a prospective cohort of hospitalized adults with CAP (1995-2011) was performed.
resultsWe documented 4121 CAP episodes, of which 983 (23.9%) occurred in patients with COPD; the median FEV1 value was 50%, and 57.8% were classified as stage III or IV in the GOLD classification. Fifty-eight per cent of patients were receiving inhaled steroids, and 14.6% chronic oxygen therapy at home. Patients with COPD presented specific clinical features. S. pneumoniae was the leading causative organism overall, but P. aeruginosa was more frequent in COPD (3.4 vs. 0.5%; p<0.001). Independent risk factors for case-fatality rate in patients with COPD were multilobar pneumonia, P. aeruginosa pneumonia, and high-risk PSI classes. Prior pneumococcal vaccination was found to be protective. FEV1 was an independent risk factor for P. aeruginosa pneumonia.
conclusionsCAP in patients with COPD presents specific characteristics and risk factors for mortality. Prior pneumococcal vaccine has a beneficial effect on outcomes. P. aeruginosa pneumonia is associated with low FEV1 values and poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.